Drug Development ProgressTakeda's TAK-861 has shown promising results in treating narcolepsy type 1, with management highlighting its potential as a leading treatment option.
Financial Guidance ConfidenceAlkermes reiterates its 2024 financial guidance, signaling strong confidence in meeting its revenue and non-GAAP net income targets for the year.
Product Sales GrowthLybalvi sales have surged, with a notable 50% increase compared to the previous year, hinting at a strong market uptake and improved commercial access.